Published in Immunology on February 01, 2010
Treating cancer with genetically engineered T cells. Trends Biotechnol (2011) 1.83
In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia. PLoS One (2016) 1.44
Advances in Gene Delivery Systems. Pharmaceut Med (2011) 1.09
Lentiviral vectors for cancer immunotherapy and clinical applications. Cancers (Basel) (2013) 0.93
Seatbelts in CAR therapy: How Safe Are CARS? Pharmaceuticals (Basel) (2015) 0.89
Specific roles of each TCR hemichain in generating functional chain-centric TCR. J Immunol (2015) 0.84
Development of safer gene delivery systems to minimize the risk of insertional mutagenesis-related malignancies: a critical issue for the field of gene therapy. ISRN Oncol (2012) 0.82
Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens. Front Immunol (2015) 0.80
How (specific) would like your T-cells today? Generating T-cell therapeutic function through TCR-gene transfer. Front Immunol (2012) 0.79
Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer. J Transl Med (2011) 0.79
Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy. Hum Vaccin Immunother (2013) 0.77
T cell avidity and tumor immunity: problems and solutions. Cancer Microenviron (2013) 0.77
Molecular insights for optimizing T cell receptor specificity against cancer. Front Immunol (2013) 0.77
Generation of V α13/β21+T cell specific target CML cells by TCR gene transfer. Oncotarget (2016) 0.75
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature (1995) 7.40
Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res (2006) 3.52
Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol (2005) 2.97
Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol (2001) 2.79
Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med (2008) 2.64
Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol (2008) 2.54
The encephalomyocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and in embryos. Mol Cell Biol (1991) 2.42
Immunotherapy through TCR gene transfer. Nat Immunol (2001) 2.41
Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res (2007) 2.20
Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin Immunol (2006) 2.20
How much TCR does a T cell need? Immunity (2001) 2.18
Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol (1999) 2.17
TCRs with high affinity for foreign pMHC show self-reactivity. Nat Immunol (2002) 2.12
Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood (2006) 2.11
Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood (2000) 1.94
Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther (2008) 1.94
In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc Natl Acad Sci U S A (2000) 1.92
High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J Immunol (2007) 1.85
Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity (2005) 1.81
Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice. J Clin Invest (2008) 1.68
The T cell receptor: critical role of the membrane environment in receptor assembly and function. Annu Rev Immunol (2005) 1.64
Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood (2006) 1.60
Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood (2005) 1.51
Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood (2003) 1.50
Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J Virol (2000) 1.47
Class II-restricted T cell receptor engineered in vitro for higher affinity retains peptide specificity and function. Proc Natl Acad Sci U S A (2005) 1.46
Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes. J Immunol (2003) 1.41
Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc Natl Acad Sci U S A (2009) 1.34
Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette. J Mol Med (Berl) (2008) 1.28
Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood (2007) 1.25
A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection. Proc Natl Acad Sci U S A (2005) 1.25
High-affinity, peptide-specific T cell receptors can be generated by mutations in CDR1, CDR2 or CDR3. J Mol Biol (2004) 1.21
Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain. J Exp Med (2009) 1.21
Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells. J Immunol (2007) 1.15
Human TCR that incorporate CD3zeta induce highly preferred pairing between TCRalpha and beta chains following gene transfer. J Immunol (2008) 1.15
Designer T cells by T cell receptor replacement. Eur J Immunol (2006) 1.14
Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells. J Immunol (2008) 1.12
Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity. Cancer Res (2006) 1.10
The study of high-affinity TCRs reveals duality in T cell recognition of antigen: specificity and degeneracy. J Immunol (2006) 1.08
Alpha beta T cell receptor transfer to gamma delta T cells generates functional effector cells without mixed TCR dimers in vivo. J Immunol (2009) 1.06
Functional reconstitution of class II MHC-restricted T cell immunity mediated by retroviral transfer of the alpha beta TCR complex. J Immunol (2000) 1.04
Lentiviral vectors for T-cell suicide gene therapy: preservation of T-cell effector function after cytokine-mediated transduction. Mol Ther (2007) 1.03
Requirements for effective antitumor responses of TCR transduced T cells. J Immunol (2008) 1.02
Allogeneic HLA-A*02-restricted WT1-specific T cells from mismatched donors are highly reactive but show off-target promiscuity. J Immunol (2011) 0.97
Transgenic TCR expression: comparison of single chain with full-length receptor constructs for T-cell function. Cancer Gene Ther (2004) 0.87
Rapid alphabeta TCR-mediated responses in gammadelta T cells transduced with cancer-specific TCR genes. Gene Ther (2009) 0.86
Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet (2005) 4.09
T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol (2010) 2.03
Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J Clin Oncol (2011) 2.01
Regulatory T cells, derived from naïve CD4+CD25- T cells by in vitro Foxp3 gene transfer, can induce transplantation tolerance. Transplantation (2005) 1.86
Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma. Blood (2010) 1.74
Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood (2003) 1.70
Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice. J Clin Invest (2008) 1.68
Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol (2008) 1.64
Specificity for the tumor-associated self-antigen WT1 drives the development of fully functional memory T cells in the absence of vaccination. Blood (2011) 1.55
CD3 limits the efficacy of TCR gene therapy in vivo. Blood (2011) 1.55
Adenoviremia has limited clinical impact in the majority of patients following alemtuzumab-based allogeneic stem cell transplantation in adults. Clin Infect Dis (2012) 1.55
DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance. Blood (2008) 1.51
Monoclonal T-cell receptors: new reagents for cancer therapy. Mol Ther (2007) 1.34
Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc Natl Acad Sci U S A (2009) 1.34
A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection. Proc Natl Acad Sci U S A (2005) 1.25
Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood (2005) 1.24
Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells. J Immunol (2007) 1.15
Challenges in T cell receptor gene therapy. J Gene Med (2012) 1.09
Optimisation of ultrasound-mediated gene transfer (sonoporation) in skeletal muscle cells. Ultrasound Med Biol (2004) 1.07
Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood (2002) 1.05
Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients. Transplantation (2003) 1.04
Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice. Haematologica (2009) 1.00
Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen. Blood (2011) 0.97
Detection of Wilms' tumor antigen--specific CTL in tumor-draining lymph nodes of patients with early breast cancer. Clin Cancer Res (2006) 0.97
Listeriolysin O expressed in a bacterial vaccine suppresses CD4+CD25high regulatory T cell function in vivo. J Immunol (2007) 0.93
Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood (2004) 0.93
Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies. Cancer Immunol Immunother (2011) 0.91
Human MHC Class I-restricted high avidity CD4(+) T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo. Oncoimmunology (2013) 0.88
Regulatory T-cell adoptive immunotherapy: potential for treatment of autoimmunity. Expert Rev Clin Immunol (2011) 0.88
CD8alpha/alpha homodimers fail to function as co-receptor for a CD8-dependent TCR. Eur J Immunol (2007) 0.88
Immunomodulation in the treatment of haematological malignancies. Clin Exp Med (2009) 0.87
Improved intensive care unit survival for critically ill allogeneic haematopoietic stem cell transplant recipients following reduced intensity conditioning. Br J Haematol (2013) 0.86
Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Biol Blood Marrow Transplant (2003) 0.86
Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses. Br J Haematol (2013) 0.86
Induction of unresponsiveness limits tumor protection by adoptively transferred MDM2-specific cytotoxic T lymphocytes. Cancer Res (2004) 0.85
Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity. Blood (2002) 0.84
T-cell receptor gene therapy for cancer: the progress to date and future objectives. Expert Opin Biol Ther (2007) 0.82
HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning. Blood (2010) 0.82
IL15 can reverse the unresponsiveness of Wilms' tumor antigen-specific CTL in patients with prostate cancer. Clin Cancer Res (2009) 0.81
Predominant or complete recipient T-cell chimerism following alemtuzumab-based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failure. Br J Haematol (2011) 0.80
Enhancing immune responses for cancer therapy. Cell Mol Immunol (2007) 0.80
Therapeutic potential of Tregs to treat rheumatoid arthritis. Semin Immunol (2011) 0.78
Broadly expressed tumour-associated proteins as targets for cytotoxic T lymphocyte-based cancer immunotherapy. Expert Opin Biol Ther (2005) 0.78
Immunotherapy with CTL restricted by nonself MHC. Methods Mol Med (2005) 0.77
A study of T cell tolerance to the tumor-associated antigen MDM2: cytokines can restore antigen responsiveness, but not high avidity T cell function. PLoS One (2007) 0.76
Generation and characterization of transgenic mice expressing a T-cell receptor specific for the tumour-associated antigen MDM2. Immunology (2008) 0.76
Development of an Escherichia coli expressing listeriolysin-O vaccine against Wilms tumor gene 1-expressing tumors. J Immunother (2009) 0.76
Outcome of major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation may be influenced by conditioning regimen. Blood (2002) 0.75
Structural and energetic evidence for highly peptide-specific tumor antigen targeting via allo-MHC restriction. Proc Natl Acad Sci U S A (2011) 0.75
Comparison of the frequency of peptide-specific cytotoxic T lymphocytes restricted by self- and allo-MHC following in vitro T cell priming. Int Immunol (2002) 0.75
T cell gene-engineering to enhance GVT and suppress GVHD. Best Pract Res Clin Haematol (2011) 0.75
Reversal of severe cholestasis caused by chronic graft-versus-host disease with the MARS liver-support device. Transplantation (2003) 0.75